Top of the morning to you, and a fine one it is. Despite a looming tropical storm and gloomy skies hovering over the Pharmalot campus, our spirits are sunny today. And why not? As the Morning Mayor taught us: Every day should be unwrapped like a precious gift. We often note this little insight, because a pick-me-up can be a good thing, especially in times such as these. Meanwhile, here are a few items of interest to help you start your day. Hope all goes well and do stay in touch. Remember, we accept saucy tips and dossiers. …

Regeneron Pharmaceuticals (REGN) says its Covid-19 antibody drug combination prevented and treated the virus in rhesus macaques and hamsters, Reuters writes. The animal study, which has not yet been peer-reviewed, found the cocktail of two monoclonal antibodies was able to “almost completely block establishment of virus infection.” The cocktail also minimized infection in a second study in which animals were infected with a higher level of the virus, but the prophylactic effect was greatly diminished with a lower dose.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy